亚洲房颤合并颅内出血史患者的口服抗凝治疗
本研究基于韩国全国数据库,比较非维生素K拮抗剂口服抗凝药(NOAC)与华法林在非瓣膜性房颤合并自发性颅内出血(ICH)史患者中的有效性与安全性。倾向评分加权后分析5712例患者,NOAC组相比华法林组缺血性卒中、ICH及复合结局风险均显著降低,且 fatal stroke、复合结局死亡和全因死亡风险也更低。
要点
- NOAC较华法林降低缺血性卒中风险(HR 0.77)和ICH风险(HR 0.66)。
- NOAC较华法林降低复合结局死亡风险(HR 0.53)和全因死亡风险(HR 0.83)。
- NOAC对致命性ICH有降低趋势但未达统计学显著性(HR 0.47)。
核心结论
- 在亚洲非瓣膜性房颤合并既往ICH患者中,NOAC较华法林显著降低ICH和缺血性卒中风险,可能是更有效且安全的治疗选择。
研究设计与样本
- 基于韩国健康保险审查与评估数据库(2010年1月至2018年4月)的全国性观察性研究。
- 纳入5712例口服抗凝药初治的非瓣膜性房颤合并既往自发性ICH患者,其中华法林组2434例,NOAC组3278例。
- 采用倾向评分加权平衡两组基线特征,平均年龄72.5岁,CHA2DS2-VASc评分4.0。
主要发现
- NOAC组较华法林组缺血性卒中风险降低(HR 0.77,95%CI 0.61-0.97)。
- NOAC组较华法林组ICH风险降低(HR 0.66,95%CI 0.47-0.92)。
- NOAC组较华法林组复合结局(缺血性卒中+ICH)风险降低(HR 0.73,95%CI 0.60-0.88)。
- NOAC组较华法林组致命性卒中风险降低(HR 0.54,95%CI 0.32-0.89),复合结局死亡风险降低(HR 0.53,95%CI 0.34-0.81),全因死亡风险降低(HR 0.83,95%CI 0.69-0.99)。
- NOAC组较华法林组致命性ICH风险有降低趋势但无统计学显著性(HR 0.47,95%CI 0.20-1.03)。
临床怎么用
- 对于亚洲非瓣膜性房颤合并既往ICH史的患者,可优先考虑NOAC而非华法林以降低卒中及出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Warfarin is associated with a better net clinical benefit compared with no treatment in patients with nonvalvular atrial fibrillation (AF) and history of intracranial hemorrhage (ICH). There are limited data on nonvitamin K antagonist oral anticoagulants (NOACs) in these patients, especially in the Asian population. We aimed to compare the effectiveness and safety of NOACs to warfarin in a large-scale nationwide Asian population with AF and a history of ICH. Methods- Using the Korean Health Insurance Review and Assessment database from January 2010 to April 2018, we identified patients with oral anticoagulant naïve nonvalvular AF with a prior spontaneous ICH. For the comparisons, warfarin and NOAC groups were balanced using propensity score weighting. Ischemic stroke, ICH, composite outcome (ischemic stroke+ICH), fatal ischemic stroke, fatal ICH, death from composite outcome, and all-cause death were evaluated as clinical outcomes. Results- Among 5712 patients with AF with prior ICH, 2434 were treated with warfarin and 3278 were treated with NOAC. Baseline characteristics were well-balanced after propensity score weighting (mean age 72.5 years and CHA2DS2-VASc score 4.0). Compared with warfarin, NOAC was associated with lower risks of ischemic stroke (hazard ratio [HR], 0.77 [95% CI, 0.61-0.97]), ICH (HR, 0.66 [95% CI, 0.47-0.92]), and composite outcome (HR, 0.73 [95% CI, 0.60-0.88]). NOAC was associated with lower risks of fatal stroke (HR, 0.54 [95% CI, 0.32-0.89]), death from composite outcome (HR, 0.53 [95% CI, 0.34-0.81]), and all-cause death (HR, 0.83 [95% CI, 0.69-0.99]) than warfarin. NOAC showed nonsignificant trends toward to reduce fatal ICH compared with warfarin (HR, 0.47 [95% CI, 0.20-1.03]). Conclusions- NOAC was associated with a significant lower risk of ICH and ischemic stroke compared with warfarin. NOAC might be a more effective and safer treatment option for Asian patients with nonvalvular AF and a prior history of ICH.
引用
- Lee SR, Choi EK, Kwon S, et al. Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage. Stroke. 2019. PMID: 31813363. doi:10.1161/STROKEAHA.119.028030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。